RetinalGenix

RetinalGenix Technologies, Inc. is a publicly held emerging medical device company focused on preventing blindness through cost-effective, large-scale retinal screening devices and real-time home monitoring imaging and physician alert systems for patients. The Mass Retinal Screening Device provides retinal imaging that captures a 200° field of view (FOV) without pupil dilation and detects the earliest stages of diabetic retinopathy to prevent blindness. This device is required to undergo the FDA’s 510(k) approval process. RetinalGeniX's second product is RetinalCamTM, the first home self-monitoring device that offers real-time ocular and retinal imaging and streaming video for physicians. This technology enables high-risk populations to send digitized retinal images to doctors and easily stream videos from home. The second device does not require FDA 510(k) approval.